

# Investigation of interactions between poly-L-lysine-coated boron nitride nanotubes and C2C12 cells: up-take, cytocompatibility, and differentiation

G Ciofani<sup>1</sup>  
L Ricotti<sup>1</sup>  
S Danti<sup>2,3</sup>  
S Moscato<sup>4</sup>  
C Nesti<sup>2</sup>  
D D'Alessandro<sup>2,4</sup>  
D Dinucci<sup>5</sup>  
F Chiellini<sup>5</sup>  
A Pietrabissa<sup>3</sup>  
M Petrini<sup>2,3</sup>  
A Menciassi<sup>1,6</sup>

<sup>1</sup>Scuola Superiore Sant'Anna, Pisa, Italy; <sup>2</sup>CUCCS-RRMR, Center for the Clinical Use of Stem Cells – Regional Network of Regenerative Medicine, <sup>3</sup>Department of Oncology, Transplants and Advanced Technologies, <sup>4</sup>Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy; <sup>5</sup>Laboratory of Bioactive Polymeric Materials for Biomedical and Environmental Applications (BIOlab), UdR INSTM, Department of Chemistry and Industrial Chemistry, University of Pisa, San Piero a Grado, Italy; <sup>6</sup>Italian Institute of Technology, Genova, Italy

Correspondence: Gianni Ciofani  
CRIM Lab, Center for Research In  
Microengineering, Scuola Superiore  
Sant'Anna, Viale Rinaldo Piaggio,  
34. 56025 Pontedera (PI), Italy  
Tel +39 050 883 019  
Fax +39 050 883 497  
Email g.ciofani@sssup.it

**Abstract:** Boron nitride nanotubes (BNNTs) have generated considerable interest within the scientific community by virtue of their unique physical properties, which can be exploited in the biomedical field. In the present *in vitro* study, we investigated the interactions of poly-L-lysine-coated BNNTs with C2C12 cells, as a model of muscle cells, in terms of cytocompatibility and BNNT internalization. The latter was performed using both confocal and transmission electron microscopy. Finally, we investigated myoblast differentiation in the presence of BNNTs, evaluating the protein synthesis of differentiating cells, myotube formation, and expression of some constitutive myoblastic markers, such as MyoD and Cx43, by reverse transcription – polymerase chain reaction and Western blot analysis. We demonstrated that BNNTs are highly internalized by C2C12 cells, with neither adversely affecting C2C12 myoblast viability nor significantly interfering with myotube formation.

**Keywords:** boron nitride nanotubes, C2C12 cells, cytocompatibility, up-take, differentiation, MyoD, connexin 43

## Introduction

Boron nitride nanotubes (BNNTs)<sup>1,2</sup> are of significant interest to the scientific community. As with carbon nanotubes (CNTs), they have attracted wide attention because of their unique and important properties for structural and electronic applications.<sup>3,4</sup> Despite their structural similarity, carbon and boron nitride nanotubes have many different properties. While both BNNTs and CNTs possess a very high Young's modulus, BNNTs exhibit chemical and thermal stability superior to CNTs.<sup>5–7</sup> They also have a constant band gap (ie, an energy difference between the top of the valence band and the bottom of the conduction band) of about 5.5 eV;<sup>8,9</sup> in contrast, CNTs vary from semi-conducting to conducting behavior, depending on their chirality and diameter.

Recent investigations have confirmed that BNNTs have excellent piezoelectric properties. *Ab initio* calculations of the spontaneous polarization and piezoelectric properties of BNNTs have demonstrated that they function as excellent piezoelectric systems with response values larger than those of piezoelectric polymers, and comparable to those exhibited by wurtzite semiconductors.<sup>10</sup> Moreover, Bai and colleagues have recently experimentally verified a deformation-driven electrical transport and the first signs of piezoelectric behavior in multiwalled BNNTs.<sup>11</sup>

These properties make BNNTs potentially attractive candidates for a wide range of applications in the nano domain.<sup>12</sup> In recent years, several applications of CNTs in the field of biotechnology have been proposed,<sup>13</sup> but the biomedical applications of BNNTs remain largely unexplored.<sup>14</sup> Zhi and colleagues investigated the interaction between BNNTs and various protein species<sup>15</sup> and between BNNTs and DNA,<sup>16</sup> but the first studies of the interactions between BNNTs and living cells were performed by the authors.<sup>17–19</sup> Despite these preliminary and interesting observations, it is mandatory to extend biological investigations to many different cell types and, eventually, *in vivo*, in order to highlight different behaviors following the treatment with BNNTs. As a matter of fact, in our experience, distinct cell types treated *in vitro* with BNNTs may respond with different dose sensitivity. Nanovector platforms are particularly complex systems that can lead to opposite phenomena up to the analyzed *in vitro* model.

In the present report, we focused our study on up-take, cytocompatibility, and differentiation of C2C12 cells, as a model of muscle cells, in presence of BNNTs. To perform such investigations, stable dispersions of BNNTs were prepared using a positively charged protein (poly-L-lysine [PLL]) as dispersion agent. PLL-coated BNNTs were also conjugated with fluorescent molecules (quantum dots) to enable their tracking in living cells.

Due to the piezoelectricity owned by BNNTs, a positive interaction between muscle cells and BNNTs would potentially allow their employment in the future, as intracellular nanotransducers conveying mechanoelectric stimulation to sensitive cells, such as myoblasts. This report lays the basic foundations for this challenge. BNNT cytocompatibility was investigated in order to identify the highest working concentration potentially usable *in vitro* without affecting cell viability; cellular up-take of BNNTs was then studied; finally, myogenic differentiative capability retained by C2C12 cells internalizing BNNTs was analyzed.

## Materials and methods

### BNNT dispersion and characterization

BNNTs (provided by the Australian National University, Canberra, Australia) were produced by using a ball milling and annealing method.<sup>20</sup> Details of sample purity and composition, as provided by the supplier, include: yield >80%, boron nitride >97 wt%, metal catalysts (Fe and Cr derived from the milling process) ~1.5 wt% and absorbed O<sub>2</sub> ~1.5 wt%.

PLL (81339, MW 70,000–150,000; Fluka, St. Louis, MO) was used for the dispersion and stabilization

of BNNTs. Dispersions were prepared with phosphate-buffered solution (PBS). BNNTs (5 mg) were mixed with 10 mL of a 0.1% PLL solution in a polystyrene tube. The samples were sonicated for 12 h (by a Branson sonicor 2510; Branson, Danbury, CT) using an output power of 20 W for all the experiments. After sonication, they were centrifuged at 1,100 g for 10 min to remove nondispersed residuals and impurities. Excess PLL was removed by ultracentrifugation three times at 30,000 g for 30 min at 4°C (Allegra 64R; Beckman Coulter, Fullerton, CA) resulting in a stable PLL-BNNT dispersion by the noncovalent coating of the nanotube walls with PLL. The concentration of BNNTs was quantified by spectrophotometric analysis, using a LIBRA S12 Spectrophotometer UV/Vis/NIR (Biochrom, Cambridge, UK) as previously reported,<sup>17</sup> while the residual concentration of PLL in the dispersions was assessed using the bicinchoninic acid (BCA) method (for details see below: Quantitative studies on differentiated C2C12 cells: double stranded (ds)-DNA and protein quantification). Microphotographs of the final dispersion of BNNTs were obtained with a Zeiss 902 transmission electron microscope (Carl Zeiss, Oberkochen, Germany), dropping a small quantity of aqueous suspension on a copper grid.

PLL-BNNTs were covalently labeled with carboxyl derivatized quantum dots for cellular tracking studies. Carboxyl quantum dots were supplied by Invitrogen (Qdot® 605 ITK™; Invitrogen, Carlsbad, CA). The conjugation reaction between the amino-groups of PLL and carboxylic-groups of quantum dots was carried out as specified by the supplier. Briefly, 4 mL of PLL-BNNT (100 µg/mL) were mixed with 8 µL of Qdots (8 µM) and 150 µL of 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (10 mg/mL, EDC, 03450; Fluka) as activator. The solution was gently stirred for 90 min at room temperature for optimal conjugation and finally centrifuged (10 min at 1,100 g) to remove large aggregates. Finally, ultracentrifugation (twice at 30,000 g for 30 min at 4°C) was performed to remove unbound quantum dots from the labeled BNNT dispersions. Qdot labeled BNNTs were exploited only for confocal investigation of the up-take: all other tests (transmission electron microscopy [TEM] analysis, cytocompatibility, differentiation) were performed on PLL-BNNTs in order to avoid any misinterpretation of the data due to the presence of Qdots on the nanotubes.

Sample size distribution was analyzed with an N4plus submicron particle size analyzer (Beckman Coulter); Z-potential measurement was performed with a Nano Z-Sizer (Malvern Instruments, Westborough, MA). Each acquisition

was performed in triplicate on aqueous nanotube suspensions at a concentration of 1  $\mu\text{g/mL}$ .

## Cell culture and BNNT tracking

C2C12 mouse myoblasts (ATCC CRL-1772) were cultured in expansion medium, constituted by Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 IU/mL penicillin, 100  $\mu\text{g/mL}$  streptomycin and 2 mM L-glutamine. Cells were maintained in normal culture conditions (37°C, saturated humidity atmosphere at 95% air/5%  $\text{CO}_2$ ). This cell line, widely used as muscle cell model,<sup>21</sup> can differentiate rapidly, in appropriate culture conditions, also forming contractile myotubes that produce characteristic muscle proteins.<sup>22</sup> In our studies, differentiation of C2C12 myoblasts in myotubes was induced by switching, in cell specimens at 80%–90% confluence, the culture medium from expansion to differentiation medium, composed of DMEM supplemented with 2 mM L-glutamine, 100 IU/mL penicillin, 100  $\mu\text{g/mL}$  streptomycin, 1% Insulin-Transferrin-Selenium ([ITS] I3146; Sigma, St. Louis, MO), and 1% FBS.

Cell internalization studies were performed by both confocal and transmission electron microscopy.

To pursue confocal analysis, 5,000 cells were seeded on coverglasses (of 1.2 cm diameter), and cultured for 3 days. Qdot labeled-BNNTs were then added to the culture medium with a final concentration of 5  $\mu\text{g/mL}$  of PLL-BNNTs and incubated with the cells for 12 h. Calcein AM (2  $\mu\text{M}$ ; Molecular Probes, Eugene, OR) was used for cell cytoplasm labeling (green fluorescence), while 5  $\mu\text{g/mL}$  of Hoechst 33342 (H1399; Invitrogen) was used for nucleus staining (blue). Confocal analysis was finally carried out using a Nikon Inverted Microscope TiE equipped with a Nikon Confocal Laser System A1Rsi (software for image analysis was NIS Elements C 3.06; Nikon Instruments, Melville, NY).

Tests using sodium azide ( $[\text{NaN}_3]$  478484; Carlo Erba, Milan, Italy), a well known endocytosis inhibitor, enabled investigation of the mechanism responsible for internalization of the BNNTs.<sup>23</sup>  $\text{NaN}_3$  acts by blocking production of adenosine triphosphate (ATP) in cells and thus the energy required for the endocytotic pathway. The cell culture was treated for 30 min with 10 mM  $\text{NaN}_3$ -modified medium and then incubated for 3 h in culture medium containing 5  $\mu\text{g/mL}$  of Qdot labeled BNNTs. Confocal analysis followed as previously described.

Internalization was also investigated by TEM. C2C12 cells were seeded at  $10^6$  cells/T25 flask. After attachment, cells

were incubated in a PLL-BNNT modified medium (at a final concentration of 5  $\mu\text{g/mL}$ ). After 12 h of incubation, samples were washed in PBS 0.1 M and thereafter fixed when still adherent to flasks with 1% w/v glutaraldehyde–4% w/v paraformaldehyde in PBS 0.1 M pH 7.2 for 2 h at 4°C. After washing, the cells were detached by scraping, post-fixed in 1% w/v  $\text{OsO}_4$  PBS 0.1 M pH 7.2 for 1 h, washed and dehydrated with acidified acetone-dimethylacetal (Fluka) for 10 min. Thus, the samples were mixed in Epon-Durcupan resin in BEEM capsules #00 (Structure Probe, West Chester, PA) overnight at room temperature and finally embedded in resin at 56°C for 48 h. Ultra-thin sections (20–30 nm thick) were obtained with an Ultratome Nova ultramicrotome (LKB, Bromma, Sweden) equipped with a diamond knife (Diatome, Biel/Bienne, Switzerland).

The sections were placed on 200 square mesh nickel grids, counterstained with saturated aqueous uranyl acetate and lead citrate solutions and observed in a Zeiss 902 transmission electron microscope (Carl Zeiss).

## Cytocompatibility assays

Both quantitative (Trypan Blue, MTT) and qualitative (LIVE/DEAD®, annexin V-FITC) assays were performed in order to assess cytocompatibility of BNNTs with C2C12 cells and to establish the maximum working concentration to use.

Cells (250,000 in T25 flasks) were incubated for 24, 48, and 72 h in standard culture conditions to determine their viability following incubation with PLL-BNNT modified media, at various concentrations: 0 (k-, as control), 5, 10, and 15  $\mu\text{g/mL}$  of BNNTs. A further control test using 3  $\mu\text{g/mL}$  of PLL was performed, corresponding to the concentration detected in the dispersion of 15  $\mu\text{g/mL}$  of PLL-BNNTs. The number of viable cells was estimated with Trypan Blue exclusion (T0887; Sigma). Briefly, cell monolayers were rinsed twice with PBS and re-suspended with trypsin and EDTA. An aliquot of the cells was immediately stained with 0.4% Trypan Blue, and the number of viable cells was determined using a hemocytometer and light microscopy.

For metabolic activity testing, MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide, M2128; Sigma) assay was carried out after 24, 48, and 72 h of incubation with PLL-BNNT modified media. After Trypan Blue counting, 30,000 viable cells were seeded in 96-well plate chambers ( $n = 6$ ). Once complete cell adhesion has been verified (about 6 h after seeding), cells were incubated with MTT 0.5 mg/mL for 4 h. The supernatant was then removed

and the cell samples were treated with 100  $\mu\text{L}$  of dimethyl sulfoxide ([DMSO], D8418; Sigma). The absorbance at 570 nm was measured with a VERSAMax microplate reader (Molecular Devices). A reference control test (k-) was included.

Viability was further investigated with the LIVE/DEAD® viability/cytotoxicity Kit (Molecular Probes). The kit contains Calcein AM (4 mM in anhydrous DMSO) and ethidium homodimer-1 [EthD-1, 2 mM in DMSO/H<sub>2</sub>O 1:4 (v/v)]. After incubation for 24, 48, and 72 h at different PLL-BNNT concentrations (0, 5, 10, and 15  $\mu\text{g/mL}$ ), cells (20,000 in 24-well plate chambers,  $n = 3$ ) were rinsed with PBS and treated for 10 min at 37°C with 2  $\mu\text{M}$  calcein AM and 4  $\mu\text{M}$  EthD-1 in PBS. A further control with 3  $\mu\text{g/mL}$  of PLL alone was performed. Cells were finally observed with an inverted fluorescence microscope (TE2000U; Nikon Instruments) equipped with a cooled CCD camera (DS-5MC USB2i; Nikon Instruments) and with NIS Elements imaging software (Nikon Instruments) equipped with the appropriate filters.

For early apoptosis detection, 20,000 cells were seeded in 24-well plate chambers ( $n = 3$ ) and treated with 0, 5, 10, and 15  $\mu\text{g/mL}$  of PLL-BNNTs for 24 h. A further control with 3  $\mu\text{g/mL}$  of PLL alone was performed. ApoAlert Kit (Clontech Laboratories, Mountain View, CA) was used to evaluate differences between normal and apoptotic cells after treatments. The kit contains annexin V-FITC (20  $\mu\text{g/mL}$  in Tris-NaCl), 1 $\times$  binding buffer and propidium iodide (50  $\mu\text{g/mL}$  in 1 $\times$  binding buffer). Cells were rinsed with 1 $\times$  binding buffer and then incubated with 200  $\mu\text{L}$  of 1 $\times$  binding buffer containing 5  $\mu\text{L}$  of the annexin V solution and 10  $\mu\text{L}$  of the propidium iodide solution. After incubation in the dark at room temperature for 20 min, cells were examined by fluorescence microscopy with the appropriate filters.

## Quantitative studies on differentiated C2C12 cells: Double stranded (ds)-DNA and protein quantification

To perform value normalization, both ds-DNA and total protein content assays were carried out in cascade on the same samples after cell lysis. Proteic production was here investigated as an index of cell synthesis compatible, although not specific, with the differentiation process.

For ds-DNA and protein quantifications on differentiated C2C12, 150,000 cells were seeded in 6-well plate chambers and when 90% of confluence was reached, the growth medium was changed to the differentiating medium.

All assays ( $n = 3$ ) were performed following 3 days of incubation with differentiating medium loaded with 0 (control cultures), 5 and 10  $\mu\text{g/mL}$  of PLL-BNNTs. Moreover, individual samples were run in triplicate to minimize operator error.

At the endpoint, the culture medium was removed from the cell samples and double distilled (dd)-H<sub>2</sub>O was added; the samples were frozen at -20°C and stored for subsequent assays. Cell lysates were thus obtained by two freeze/thaw cycles of the samples: overnight freezing at -20°C, 10 min thawing at 37°C in a water bath with stirring for 15 s to enable both the ds-DNA and the proteins to go into solution.

Ds-DNA content in cell lysates was measured using the PicoGreen kit (Molecular Probes<sup>24</sup>). The PicoGreen dye binds to ds-DNA and the resulting fluorescence intensity is directly proportional to the ds-DNA concentration in solution. Standard solutions of DNA in ddH<sub>2</sub>O at concentrations ranging from 0–6  $\mu\text{g/mL}$  were prepared and 50  $\mu\text{L}$  of standard or sample was loaded for quantification in a 96-well black microplate. Working buffer and PicoGreen dye solution were prepared according to the manufacturer's instructions and 100 and 150  $\mu\text{L}$ /well added, respectively. After a 10 min incubation in the dark at room temperature, fluorescence intensity was measured on a plate reader (Victor3; PerkinElmer, Waltham, MA) using an excitation wavelength of 485 nm and an emission wavelength of 535 nm.

Total protein concentration was determined by the BCA method (Pierce Biotechnology, Rockford, IL<sup>25</sup>) following the microplate procedure. Cell lysates and working reagent were loaded inside a 96-well microplate at 25 and 200  $\mu\text{L}$ /well, respectively. The microplate was gently shaken and then incubated at 37°C for 30 min. Samples were cooled down to room temperature and absorbance was read at 562 nm on a plate reader (BioRad Laboratories, Hercules, CA). Protein concentration of cellular specimens was then obtained by reference to bovine serum albumin (BSA) standards. Finally, total protein content was normalized by DNA content as determined by the PicoGreen assay.

Additionally, cell morphology observation by inverted light microscopy on hematoxylin–eosin (H&E) stained specimens was carried out on cell samples analogous to the ones previously described. Briefly, samples were fixed with 1% buffered formalin at 4°C for 10 min, stained with for 5 s with hematoxylin, rinsed in tap water for 5 s, stained with eosin for 1 s, washed in tap and distilled water, and finally dried at room temperature.



Formation of multinucleated myotubes was assessed with Hoechst staining and observation with fluorescence microscope. Grade of differentiation was quantitatively evaluated calculating the fusion index of the cultures, determined by dividing the total number of nuclei in myotubes ( $\geq 2$  nuclei) by the total number of nuclei counted.<sup>26</sup> More than 30 myotubes were analyzed for each assay (experiments performed in triplicate).

## Reverse transcription-polymerase chain reaction (RT-PCR) for detection of MyoD and connexin 43 (Cx43) mRNA in differentiated C2C12 cells

C2C12 cells were cultured as described in the previous section. Assays were performed after 3 days of incubation with standard differentiating medium (control cultures) followed by 3 days of differentiating medium, containing either 0, 5, or 10  $\mu\text{g/mL}$  of PLL-BNNTs.

Total RNA was isolated from cell cultures using High Pure RNA Isolation kit (Roche, Basel, Switzerland) according to the manufacturer's protocol. RNA concentration was measured in a spectrophotometer at 260 nm. Identical amounts of RNA were reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis kit (Roche). Treatment with DNase I (Invitrogen) was performed following the manufacturer's indications. Subsequently, cDNA was amplified by PCR with the specific primers and procedures listed in Table 1. The housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was used as internal standard. Each RT-PCR was performed at least twice. The PCR products were loaded on a 2.5% agarose gel and stained with ethidium bromide.

**Table 1** Primer sequences and conditions for RT-PCR analysis

Gene	Sequence	Size (bp)	Cycle
GAPDH	5'-AGAACATCATCCCTGCATCC-3'	183	35 cycles:
	5'-CCTGCTTCACCACTTCTTG-3'		30 sec, 94°C 30 sec, 54°C 30 sec, 72°C
MyoD	5'-TTCTATGACGACCCGTGTTT-3'	300	35 cycles:
	5'-GGCCTCATTACTTGTCTCA-3'		45 sec, 94°C 45 sec, 54°C 45 sec, 72°C
Cx43	5'-GCGCAGAGCAAAATCGAA-3'	206	35 cycles:
	5'-AATCTCCAGGTCATCAGG-3'		60 sec, 95°C 30 sec, 55°C 30 sec, 72°C

**Abbreviation:** RT-PCR, reverse transcription-polymerase chain reaction.

## Gel electrophoresis and Western blot for MyoD and Cx43 detection in differentiated C2C12 cells and immunocytochemistry for MyoD

C2C12 pellets obtained from control cultures and cultures treated with 0, 5 and 10  $\mu\text{g/mL}$  of PLL-BNNTs (see previous Section for details) were washed in Dulbecco's modified phosphate saline buffer (D-PBS; Sigma Aldrich), resuspended in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2  $\mu\text{g/mL}$  Aprotinin, 2  $\mu\text{g/mL}$  Pepstatin, 10  $\mu\text{M}$  Leupeptin, 200  $\mu\text{M}$  NaVO<sub>3</sub> and 200  $\mu\text{M}$  NaF) and incubated for 30 min in an ice bath, vortexing every 10 min. Cell lysates were then centrifuged at 15,000 rpm for 20 min at 4°C, supernatants were recovered and protein concentration was determined for all the samples using the BCA method.

Proteins (30  $\mu\text{g}$ ) from the supernatant were separated on a 10% polyacrylamide gel under reducing conditions, transferred to a polyvinylidene fluoride (PVDF) membrane (Immobilon-P; Millipore, Bedford, MA) and probed with either mouse monoclonal anti-MyoD antibody (Santa Cruz, Santa Cruz, CA), or with mouse monoclonal anti-connexin 43 (Santa Cruz), or with mouse monoclonal anti- $\beta$ -actin (Sigma Aldrich) as internal control of the total protein content. SNAP i.d. system (Millipore) was used to probe PVDF membranes. Briefly, PVDF membranes were placed in the device holders, saturated in 0.1% Tween Tris-buffered saline (T-TBS) containing 0.25% dry fat-free milk (immediately eliminated by vacuum application) and incubated for 10 min with either anti-MyoD (1:100 in T-TBS), or anti-Cx43 (1:10,000 in T-TBS), or anti- $\beta$ -actin (1:2,000 in T-TBS) antibodies, respectively. After three washings in T-TBS under vacuum application, the membranes were incubated with goat anti-mouse immunoglobulin-horseradish peroxidase conjugate (KPL, 1:2,000 in T-TBS). Five washings with T-TBS were performed (under vacuum application) and the immunocomplexes were then detected on PVDF membranes by chemiluminescence (ECL Turbo; Euroclone, Milan, Italy) according to the manufacturer's instructions.

For immunocytochemical analysis of MyoD, C2C12 were seeded at a cell density of  $10^4$  cells/well onto chamber slides and cultured either with or without BNNT (5  $\mu\text{g/mL}$ ). Thereafter, the cells were fixed with 1% buffered formalin in PBS for 10 minutes at 4°C and then washed in PBS. MyoD antigen retrieval was performed in citrate buffer pH 6.0 (Diapath, Bergamo, Italy) with microwaves (6  $\times$  5 min at 600 W). Aspecific antibody binding sites

were saturated by normal goat serum (Vector Laboratories, Burlingame, CA) 1:20 in PBS (for 20 min at 37°C); the cells were then incubated overnight at 4°C either with the specific anti-MyoD antibody (1:50 PBS containing 0.1% BSA) or without primary antibody, as negative control.

MyoD antibody binding was revealed using the ABC kit (Vector Laboratories) and diaminobenzidine (DAB; GeneTex, San Antonio, TX) as chromogen substrate. Moreover, the cells were counterstained by hematoxylin and subsequently dehydrated in a graded series of ethanol, clarified with xylene and mounted with DPX balsam. The samples were observed by an optical microscope.


## Statistical analysis

Analysis of the data was performed by analysis of variance (ANOVA) followed by Student's *t*-test to test for significance, which was set at 5%. MTT tests were performed in triplicate; all the other assays in triplicate. In all cases, three independent experiments were carried out. Results are presented as mean value  $\pm$  standard error of the mean (SEM).

## Results and discussion

### Interactions between C2C12 cells and BNNTs

Stable dispersions of BNNTs were obtained by means of PLL as a dispersion agent. PLL is a cytocompatible polymer with positive amino-terminal groups. Figure 1 shows a TEM image of a 200  $\mu\text{g/mL}$  dispersion after preparation: both single nanotubes (red arrows) and small aggregates of nanotubes are visible, with a size congruent to the results achieved with the dynamic light scattering analysis, that




**Figure 1** TEM image of PLL-BNNT dispersion: both single nanotubes (red arrows) and small aggregates of nanotubes are visible.

yielded an average particle value of  $242 \pm 92$  nm. Moreover, Z-potential analysis revealed a strong positive Z-potential ( $43.40 \pm 3.26$  mV), highlighting the high stability of the dispersions. After the preparation procedure, the residual PLL concentration, evaluated with the BCA method, resulted to be about 1:5 w/w with respect to that of the BNNTs present in the dispersion (ie, for a dispersion containing 15  $\mu\text{g/mL}$  of BNNTs, residual PLL concentration was about 3  $\mu\text{g/mL}$ ).

Figure 2 shows the results of the internalization assays performed with confocal microscopy. Figure 2a depicts consecutive slides of cells (magnification 60X, z-stack step 500 nm) following incubation with BNNTs, showing Qdot-labelled BNNTs (red) strongly internalized in the cell cytoplasm (green). No evidence of BNNTs in the nuclei (blue) of cells was observed.

These observations demonstrated that PLL-BNNTs were internalized by the cells, but provided no information on the nature of the mechanism responsible for this up-take. Sodium azide was exploited to investigate the energy-dependence of the up-take mechanism of PLL-BNNTs. The chosen incubation time was 30 min, as optimal compromise between effective ATP blocking by sodium azide, and reduced cytotoxic effects resulting from a prolonged energy deficiency. Figure 2b shows a confocal image of cells incubated for 1 h in a medium containing 5  $\mu\text{g/mL}$  of Qdot-labelled BNNTs: internalization occurred as shown in the previous tests. An image of C2C12 cells analogously incubated but following pre-treatment with sodium azide is shown in Figure 2c. Here a clear inhibition of cell up-take was evidenced by a negligible amount of internalized BNNTs and a massive BNNT accumulation on the cell membrane. This result demonstrates that the internalization of PLL-BNNTs by C2C12 is energy-dependent, as already noticed for PEI-coated BNNTs in other cell lines.<sup>18</sup>

TEM analysis reported in Figure 3a confirmed that PLL-BNNTs are abundantly internalized by C2C12 cells, showing the presence of noncellular electron-dense material, compatible for appearance and dimensions with BNNTs (see Figure 1), in cytoplasmic vacuoles. Arrows are used to indicate the vacuoles/vesicles in the intracellular environment. Figure 3b, as control, shows C2C12 cells cultured in the same conditions but without BNNT treatment: absence of BNNT-like material in the cytoplasmic compartments is evident. Such observations are consistent with those of Yehia and colleagues,<sup>27</sup> Raffa and colleagues,<sup>28</sup> and Tutak and colleagues<sup>29</sup> performed on carbon nanotubes: in these studies different kinds of mammalian cells were exposed to CNTs dispersed in cell growth medium that presented




**Figure 2** Confocal analysis of BNNT internalization **a**) and investigation of its mechanism: BNNT uptake **b**) and its inhibition after treatment with sodium azide **c**).



high-resolution TEM images of dense dark material within intracellular vacuoles.

The data concerning the effects of BNNT up-take are reported in Figure 4.

Viability assays show that after 24, 48, and 72 h of incubation at different PLL-BNNT concentrations (5, 10, and 15  $\mu\text{g/mL}$ ), cell densities did not differ from their respective controls. In all cases, preliminary cell viability assessed with Trypan Blue was greater than 90%. The data at 72 h confirmed that BNNTs did not affect cellular replication: the cells reached confluence in each test, undergoing almost three complete replication cycles. The same considerations are valid for controls performed with 3  $\mu\text{g/mL}$  of PLL, ie, the amount of PLL present in the highest concentrated BNNT sample.



**Figure 3** TEM imaging of C2C12 cells incubated for 12 h with (a) and without (b) a 10  $\mu\text{g/mL}$  BNNT modified medium. The TEM micrograph shows C2C12 with vesicles containing BNNT (arrows) in the treated sample. Magnification 7000 $\times$ .

**Abbreviations:** BNNT, boron nitride nanotubes; M, mitochondria; N, nuclei; TEM, transmission electron microscopy.

Figure 4 shows MTT results for each test. C2C12 exhibited a slight decrease in metabolic activity following incubation with PLL-BNNTs. Cells incubated with 5  $\mu\text{g/mL}$  of nanotubes sustained a decrease of about 10% after 24, 48, and 72 h of incubation, but all these results were not statistically different from the respective controls (in all cases,  $P > 0.05$ ). Similar results were obtained by culturing C2C12 with 10  $\mu\text{g/mL}$  of PLL-BNNTs. Incubation with 15  $\mu\text{g/mL}$  of nanotubes provided a nonsignificant MTT reduction after 24 and 48 h (about 15%;  $P > 0.05$ ), but the decrease in metabolic activity became significant (about 20%;  $P < 0.05$ ) by the third day. The same trend was followed by cells incubated with 3  $\mu\text{g/mL}$  of PLL alone (statistical significance after 3 days of incubation), thus demonstrating that, at these concentrations, the slight cytotoxicity is mainly due to the surfactant rather than to a negative effect of the nanotubes.


On the basis of these results, we decided to use 5 and 10  $\mu\text{g/mL}$  as the working concentrations for the subsequent studies.

Optimal cell viability up to 10  $\mu\text{g/mL}$  of BNNTs was confirmed by the LIVE/DEAD<sup>®</sup> viability/cytotoxicity assay. Live cells are distinguished by the presence of ubiquitous intracellular esterase activity, determined by the enzymatic conversion of the nonfluorescent cell-permeant agent, calcein AM, to an intensely fluorescent molecule, calcein. Calcein is well retained within live cells, producing an intense uniform green fluorescence. Conversely, EthD-1 enters cells with damaged membranes and undergoes a 40-fold enhancement of fluorescence upon binding to nucleic acids, thereby producing a bright red fluorescence in dead cells. EthD-1 is excluded by the intact plasma membrane of live cells.

Figure 5 shows the results of the viability/cytotoxicity assay, performed after 24, 48, and 72 h of incubation with 0, 5, 10, and 15  $\mu\text{g/mL}$  of BNNTs. A further test with 3  $\mu\text{g/mL}$  of PLL alone was also carried out. No evidence of cell membrane damage was present following treatment of C2C12 cells up to 10  $\mu\text{g/mL}$  of PLL-BNNTs, clearly demonstrating optimal cell viability, completely comparable to that of the control cells (0  $\mu\text{g/mL}$ ). A nonnegligible amount of red stained cells was present in the samples treated with either 15  $\mu\text{g/mL}$  of PLL-BNNTs or 3  $\mu\text{g/mL}$  of PLL, thus confirming the MTT assay quantitative results.

Early apoptotic phenomena were investigated as described in Cytocompatibility assays. One of the methods employed to study apoptosis detects changes in the position of phosphatidylserine (PS) in the cell membrane. In nonapoptotic cells, most PS molecules are localized on the inner layer of the plasma membrane, but soon





**Figure 4** MTT assay results after 24, 48, and 72 h of incubation of C2C12 cells with 0, 5, 10, and 15 µg/mL of PLL-BNNTs, and with 3 µg/mL of PLL ( $n = 6$ ).

after the initiation of apoptosis, PS is redistributed to the outer layer of the membrane, and becomes exposed to the extracellular environment.<sup>30</sup> Exposed PS can be easily detected with annexin V, a 35.8 kDa protein with strong affinity for PS.

Propidium iodide (PI) is a DNA red fluorescent intercalating agent; it is membrane impermeant and generally excluded from viable cells. Therefore, it can be used jointly with annexin V-FITC to differentiate necrotic (red stained), early apoptotic (green stained), apoptotic (green and red stained) and normal cells (unstained).

Figure 5 also shows the results of apoptotic assay carried out on C2C12 cells incubated for 24 h with 0, 5, 10, and 15 µg/mL of PLL-BNNTs and a control culture incubated with 3 µg/mL of PLL. No evidence of apoptosis was observed in all the treatments, with a few dead cells in the sample treated with 15 µg/mL of PLL-BNNTs or 3 µg/mL of PLL. Such observations are again in agreement with the results obtained with the LIVE/DEAD<sup>®</sup> assay and the Trypan Blue test.

Taken together, these findings clearly demonstrate the absence of significant negative effects of PLL-BNNTs on C2C12 myoblasts up to a concentration of 10 µg/mL.


## C2C12 differentiation

Differentiation of C2C12 myoblasts (80%–90% confluent) in myotubes was obtained after a 3-day culture of these

samples under differentiating conditions (1% FBS, 1% ITS). Cultures supplemented with PLL-BNNTs were monitored and compared to control cultures as previously reported, in order to verify whether BNNTs may contrast the differentiation process. Proliferation and protein synthesis of differentiating myoblasts were assessed after 3 days of incubation in differentiating medium supplemented with 0, 5 and 10 µg/mL of PLL-BNNTs by measuring ds-DNA and total protein contents.

Cultures treated with 5 µg/mL of PLL-BNNTs versus controls exhibited a nonsignificant drop in ds-DNA amount (<2%), but corresponding to a more sustained increase in protein content (about 15%). Consequently, when normalized by ds-DNA (and therefore by cell number), the total proteins resulted in a significant rise (about 20%), which was statistically different with respect to the control ( $P < 0.05$ ). Quantitative results showed that normalized protein content is about 92 µg/µg-DNA in BNNT-treated samples, whereas it is about 78 µg/µg-DNA in controls. Cultures treated with 10 µg/mL of PLL-BNNTs versus controls exhibited DNA increment (about 10%) and slight protein decrement (about 3%), resulting in a normalized protein content of about 70 µg/µg-DNA in BNNT-treated samples, nonsignificantly different from the control.

These findings, summarized in Figure 6, confirmed that in presence of BNNTs C2C12 cells retained a good protein synthesis capacity under differentiating conditions.



**Figure 5** LIVE/DEAD® viability/cytotoxicity assay and early apoptotic detection (annexin V-FITC/PI assay) performed for different incubation times and concentrations. **Note:** Scale bar: 100 µm.


The morphology of differentiating cells was assessed by phase contrast microscopy and H&E staining after 3 days of culture. Figure 7 shows differentiated C2C12 cultured with 0 (a), 5 (b), and 10 (c) µg/mL of PLL-BNNTs, demonstrating that treated cells developed myotubes without qualitative differences from the control cultures.

Quantitative assessment of myotube formation was performed evaluating the fusion index of the three different cultures (Figure 7d). Also in this case, no statistically significant differences were observed between samples treated with 0, 5 and 10 µg/mL of BNNTs: in all experiments the calculated fusion index was higher than 25% ( $P > 0.5$ ), indicating well sustained differentiative processes.

We can therefore conclude that BNNTs showed a negligible effect on the proliferation of differentiating C2C12 myoblasts; moreover, they were found to affect neither the cellular protein synthesis nor the qualitative/quantitative development of myotubes *in vitro*.

C2C12 cell differentiation was also investigated throughout the expression of some constituent myoblastic markers, such as MyoD and Cx43, both at the gene and protein level.

Differentiation of myogenic cells is regulated by multiple factors. Among these MyoD is known to play a key role in regulating myoblast differentiation. MyoD belongs to a family of proteins known as myogenic regulatory factors (MRFs).<sup>31</sup> Some of these bHLH (basic helix loop helix) transcription



**Figure 6** Total protein content normalized by ds-DNA content in C2C12 cell differentiated in presence of 0, 5, and 10 µg/mL of PLL-BNNTs ( $n = 3$ ,  $*P < 0.05$ ).

factors act synergistically, others sequentially in the myogenic differentiation cascade. MRF family members include MyoD, Myf5, myogenin, and MRF4 (Myf6). MyoD is one of the earliest markers of myogenic commitment, being expressed in activated satellite cells and in their progenitors.<sup>32</sup>

Connexins, such as Cx43, are proteins present in the myoblasts involved in the formation of gap junctions, composed of connexin-based connexons. Such junctions regulate the intercellular passage of small molecules, including inorganic ions, small metabolites and second messengers, thus achieving electrical, as well as metabolic, coupling of the cells.<sup>33</sup>

Figure 8a shows MyoD and Cx43 mRNA levels in differentiated C2C12 cells treated with 0, 5 and 10 µg/mL of PLL-BNNTs, as obtained by RT-PCR. These results highlighted that the expression of both Cx43 and MyoD genes was not drastically affected by the administration of BNNTs at a concentration lower than 10 µg/mL: Cx43 and MyoD mRNAs were found to be well expressed in all the tested samples.

Western blot analysis fully agrees with the RT-PCR results: Figure 8b shows a good synthesis level of both Cx43 and MyoD proteins for all the tested concentrations. Finally, immunocytochemistry highlighted the main nuclear localization of MyoD, with no appreciable difference between BNNT-treated and untreated cells. Cytoplasmatic detection of MyoD was only visible in mitotic cells.

All together, these results corroborated the findings obtained using the fusion index evaluation and the qualitative analysis of the myotube morphology reported in Figure 7. Therefore, myotube formation resulted to be neither inhibited


nor delayed by BNNT up-take, indicating that BNNTs in the tested range can be compatible with C2C12 differentiation.

## Conclusions

In sharp contrast to the applications of CNTs, that have been proposed in biotechnology in recent years, the biomedical applications of BNNTs have received scant attention despite their unique and impressive chemical and physical properties. As regards CNTs, a huge amount of data can be found in the literature about their biocompatibility,<sup>34</sup> often with contrasting results, and the possibility of demonstrating the safety of these nanomaterials is quite remote. On the contrary, a few studies are available for BNNTs, hence the importance to pursue rational and systematic investigations of the interactions between BNNTs and living matter.

In this paper, we reported on the results of the interaction between PLL-coated BNNTs and C2C12 myoblasts, as model of skeletal muscle cells. After obtaining a stable dispersion of BNNTs based on PLL wrapping, we used confocal microscopy and TEM analysis to demonstrate that a high internalization of PLL-BNNTs, following an energy-dependent mechanism, occurred in C2C12 cells. Moreover, cytocompatibility assays performed on C2C12 myoblasts denoted excellent proliferation and metabolic activity up to a concentration of 10 µg/mL of PLL-BNNTs and up to a 72 h culture time. At these concentrations, apoptotic, necrotic and membrane permeabilisation phenomena were completely absent, as demonstrated by both the annexin V-FITC/PI assay and the LIVE/DEAD® test. Differentiation of C2C12 cells






**Figure 7** Light microscopy on H&E-stained cell samples showing myotube formation: differentiated C2C12 cultured with 0 (a), 5 (b), and 10 (c) µg/mL of PLL-BNNTs; fusion index evaluated for the three cultures (d).

**Abbreviations:** BNNTs, boron nitride nanotubes; H&E, hematoxylin–eosin; PLL, poly-L-lysine.





**Figure 8** RT-PCR results for MyoD and Cx43 expression in C2C12 cells differentiated in presence of 0, 5, and 10 µg/ml of PLL-BNNTs; GAPDH was used as internal standard (a) Western blot results for MyoD and Cx43 production in the same cultures; β-actin was used as internal standard (b) Immunocytochemical analysis for MyoD expression on BNNT-treated cell samples (c) and controls without BNNTs (d) "Bn" indicates visible dotting in the cytoplasm due to BNNTs, the arrows indicate MyoD positive cells at nuclear level, while the arrowhead indicates MyoD positive cells at cytoplasm level.

**Abbreviations:** BNNTs, boron nitride nanotubes; H&E, hematoxylin–eosin; PLL, poly-L-lysine; RT-PCR, reverse transcription – polymerase chain reaction.

and formation of myotubes did not prove to be significantly affected by incubation with BNNT-modified differentiating medium for 72 h. The protein content of the differentiating cells was comparable or even superior in treated with respect to control cultures; mRNA of constitutive myoblastic markers, such as MyoD and Cx43, resulted to be still expressed in cells treated up to 10 µg/ml of BNNTs. Moreover, Western blot analysis showed a similar MyoD and Cx43 synthesis in all the treated samples, thus confirming no severe adverse effects on C2C12 differentiation.

Collectively, these experimental findings confirm that BNNTs are suitable for the development of novel nanovectors for biomedical applications. The exploitation of their peculiar physical properties, especially piezoelectricity, could in fact provide the basis for clinical electrostimulation therapies for various cardiac, skeletal and visceral muscular, and neurogenic disorders.

## Acknowledgments

The work described in this paper was partially supported by the IIT (Italian Institute of Technology) Network. The authors gratefully acknowledge the Australian National University of Canberra, and in particular Dr Jun Yu and Prof Ying Chen from the Department of Electronic Materials and Engineering, Research School of Physical Sciences and Engineering for providing the BNNT sample tested in this work. Moreover, the authors wish to thank Dr Matilde Masini (Department of Experimental Pathology BMIE, University of Pisa, Pisa, Italy) for TEM technical support. The authors report no conflicts of interest in this work.

## References

1. Chopra NG, Luyken RJ, Cherrey K, et al. Boron-nitride nanotubes. *Science*. 1995;269(5226):966–967.
2. Golberg D, Bando Y, Tang C, Zhi C. Boron nitride nanotubes. *Adv Mater*. 2007;19(18):2413–2432.

3. Terrones M, Romo-Herrera JM, Cruz-Silva E, et al. Pure and doped boron nitride nanotubes. *Mater Today*. 2007;10(5):30–38.
4. Zhi C, Bando Y, Tang C, Honda S, Kuwahara H, Golberg D. Boron nitride nanotubes/polystyrene composites. *J Mater Res*. 2006;21(11):2794–2800.
5. Song J, Huang Y, Jiang H, Hwang KC, Yu MF. Deformation and bifurcation analysis of boron-nitride nanotubes. *Int J Mech Sci*. 2006;48(11):1197–1207.
6. Suryavanshi AP, Yu MF, Wen J, Tang C, Bando Y. Elastic modulus and resonance behavior of boron nitride nanotubes. *App Phys Lett*. 2004;84(14):2527–2529.
7. Chen Y, Zou J, Campbell SJ, Le Caer G. Boron nitride nanotubes: pronounced resistance to oxidation. *Appl Phys Lett*. 2004;84(13):2430–2432.
8. Oku T, Koi N, Suganuma K. Electronic and optical properties of boron nitride nanotubes. *J Phys Chem Solids*. 2008;69:1228–1231.
9. Farmanzadeh D, Ghazanfary S. First principle electric field response of single-walled boron nitride nanotube: a case study of zigzag (4,0) model. *Struct Chem*. 2009;20(4):709–717.
10. Dai Y, Guo W, Zhang Z, Zhou B, Tang C. Electric-field-induced deformation in boron nitride nanotubes. *J Phys D Appl Phys*. 2009;42(8):085403.
11. Bai XD, Golberg D, Bando Y, Zhi CY, Tang C, Mitome M. Deformation-driven electrical transport of individual boron nitride nanotubes. *Nano Lett*. 2007;7(3):632–637.
12. Golberg D, Bai X, Mitome M, Tang C, Zhi C, Bando Y. Structural peculiarities of in-situ deformation of an individual boron nitride nanotube inside a high-resolution transmission electron microscope. *Acta Mater*. 2007;55(4):1293–1298.
13. Lacerda L, Bianco A, Prato M, Kostarelos K. Carbon nanotubes as nanomedicines: from toxicology to pharmacology. *Adv Drug Deliv Rev*. 2006;58(14):1460–1470.
14. Ciofani G, Raffa V, Menciassi A, Cuschieri A. Boron nitride nanotubes: an innovative tool for nanomedicine. *Nano Today*. 2009;4(1):8–10.
15. Zhi C, Bando Y, Tang C, Golberg D. Immobilization of proteins on boron nitride nanotubes. *J Am Chem Soc*. 2005;127(49):15996–15997.
16. Zhi C, Bando Y, Wang W, Tang C, Kuwahara H, Golberg D. DNA-mediated assembly of boron nitride nanotubes. *Chem Asian J*. 2007;2(12):1581–1585.
17. Ciofani G, Raffa V, Menciassi A, Dario P. Preparation of boron nitride nanotubes aqueous dispersions for biological applications. *J Nanosci Nanotechnol*. 2008;8(12):6223–6231.
18. Ciofani G, Raffa V, Menciassi A, Cuschieri A. Cytocompatibility, interactions and uptake of polyethyleneimine-coated boron nitride nanotubes by living cells: confirmation of their potential for biomedical applications. *Biotechnol Bioeng*. 2008;101(4):850–858.
19. Ciofani G, Raffa V, Menciassi A, Cuschieri A. Folate functionalised boron nitride nanotubes and their selective uptake by glioblastoma multiforme cells: implications for their use as boron carriers in clinical boron neutron capture therapy. *Nanoscale Res Lett*. 2009;4(2):113–121.
20. Yu J, Chen Y, Wuhler R, Liu Z, Ringer SP. In situ formation of BN nanotubes during nitriding reactions. *Chem Mater*. 2005;17:5172–5176.
21. Nedachi T, Fujita H, Kanzaki M. Contractile C2C12 myotube model for studying exercise-inducible responses in skeletal muscle. *Am J Physiol Endocrinol Metab*. 2008;295(5):E1191–E1204.
22. Lee JH, Tachibana H, Morinaga Y, Fujimura Y, Yamada K. Modulation of proliferation and differentiation of C2C12 skeletal muscle cells by fatty acids. *Life Sci*. 2009;84(13–14):415–420.
23. Shi Kam NW, Liu Z, Dai H. Carbon nanotubes as intracellular transporters for proteins and dna: an investigation of the uptake mechanism and pathway. *Angew Chem Int Ed*. 2006;45(4):577–581.
24. Singer VL, Jones LJ, Yue ST, Haugland RP. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. *Anal Biochem*. 1997;249(2):228–238.
25. Stoscheck CM. Quantitation of protein. *Method Enzymol*. 1990;182:50–69.
26. Charrasse S, Comunale F, Fortier M, Portales-Casamar E, Debant A, Gauthier-Rouviere C. M-cadherin activated Rac1 GTPase through the Rho-GEF trio during myoblast fusion. *Mol Biol Cell*. 2007;18:1734–1743.
27. Yehia HN, Draper RK, Mikoryak C, et al. Single-walled carbon nanotube interactions with HeLa cells. *J Nanobiotechnology*. 2007;5:8.
28. Raffa V, Ciofani G, Nitodas S, et al. Can the properties of carbon nanotubes influence their internalization by living cells? *Carbon*. 2008;46:1600–1610.
29. Tutak W, Park KH, Vasilov A, et al. Toxicity induced enhanced extracellular matrix production in osteoblastic cells cultured on single-walled carbon nanotube networks. *Nanotechnology*. 2009;20(25):255101.
30. Martin SJ, Reutelingsperger CP, McGahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. *J Exp Med*. 1995;182:1545–1556.
31. Noda T, Fujino T, Mie M, Kobatake E. Transduction of MyoD protein into myoblasts induces myogenic differentiation without addition of protein transduction domain. *Biochem Biophys Res Commun*. 2009;382(2):473–477.
32. Kanisicak O, Mendez JJ, Yamamoto S, Yamamoto M, Goldhamer DJ. Progenitors of skeletal muscle satellite cells express the muscle determination gene, MyoD. *Dev Biol*. 2009;332(1):131–141.
33. El Oakley R, Yacoub MH, Suzuki K, et al. Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart. *J Thorac Cardiovasc Surg*. 2001;122(4):759–766.
34. Smart SK, Cassady AI, Lu GQ, Martin DJ. The biocompatibility of carbon nanotubes. *Carbon*. 2006;44(6):1034–1047.

## International Journal of Nanomedicine

### Publish your work in this journal

The International Journal of Nanomedicine is an international, peer-reviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine,

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-nanomedicine-journal>

Dovepress

Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.